Otsuka Reaches $900M Deal For Oncology Drug Co. Astex
The acquisition is part of Otsuka's efforts to bolster its future earnings by focusing on potential cancer drugs, Nikkei reported.
Astex stock rose 23.8 percent, to $8.27 per share, on the Nasdaq on Wednesday.
The news comes roughly a month after Otsuka subsidiary Otsuka Techno Corp. said it and Nanjin Otsuka Techbond Techno Co. Ltd. would take an...
To view the full article, register now.